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Expression of HLA class I molecules is essential for the
recognition of tumor cells by CD81 T cells. In this
study, 48 bioptic samples of 42 patients in all stages of
melanoma were investigated after short-time cultivation
of tumor cells. To confirm melanocytic origin of cultured
cells, samples were screened for mRNA expression of
melanoma markers gp100, tyrosinase, MAGE-3, MelanA,
and MUC18 by reverse transcriptase-polymerase chain
reaction. Surface expression of specific HLA-A and -B
allospecificities on melanoma cells were analyzed with a
standard microcytotoxicity assay after stimulation with
interferon (IFN)-a and compared with the background
found in peripheral blood mononuclear cells from the
corresponding patients. Immunohistochemistry and flow
cytometry confirmed specific losses in cases where the
appropriate monoclonal antibodies were available. The
level of expression of HLA-I, HLA-II, and intercellular
Efficient specific recognition of malignant cells in melanomaand other neoplasms by the immune system requires surfaceexpression of HLA antigens. Loss or downregulation ofthese proteins is one of several mechanisms resulting inimmune-escape of metastasizing cells (Marincola et al,
1994). The expression levels of HLA class I and II on the surface of
tumor cells have been examined extensively (Ferrone and Marincola,
1995; Garrido et al, 1997) and the following abnormalities were found
in melanoma cells: (i) nonfunctional β2-microglobulin (β2M) leads to
a total loss of HLA-I restricted recognition by cytotoxic T lymphocytes
(CTL) (D’Urso et al, 1991), but increases susceptibility to lysis mediated
by natural killer cells (Maio et al, 1991); (ii) genomic loss resulting in
expression of only one HLA haplotype (Marincola et al, 1994); (iii)
locus specific downregulation due to defects in the transporters
associated with antigen processing (Cromme et al, 1994; Keating et al,
1995; Straten et al, 1997); and (iv) selective loss of class I allospecificities,
which impairs the ability of a malignant cell to present a specific
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adhesion molecule 1 antigens on melanoma cells cultured
in the presence or absence of IFN-a and IFN-g was
determined cytofluorometrically. All cell cultures tested
were found to be positive for one or more melanocytic
markers by reverse transcriptase-polymerase chain reac-
tion. The specific HLA-I alleles on the cultured cells were
detectable in 45 of 48 samples. In 11 cases a specific loss
of one HLA-I allele was observed (23A2, B7, B8, B18,
43B44, B47, B49). Ten of these samples were derived
from locoregional lymphnode metastases or from distant
metastatic tumors. Only one sample from a primary
melanoma showed a specific loss of HLA-I (B47). IFN-a
upregulated expression of HLA-I up to 4-fold. IFN-g
enhanced the appearance of HLA-II up to 35-fold and
the expression of intercellular adhesion molecule 1 up
to 40-fold. Selective loss of HLA-I allospecificities might
be a major step in tumor progression. Key words: HLA-
I/HLA-II/ICAM-1. J Invest Dermatol 111:497–502, 1998
restriction element to lymphocytes (Kageshita et al, 1993a; Rivoltini
et al, 1995; Luboldt et al, 1996).
Most studies, however, have limited the analysis to the mono-
morphic component of HLA-I (Ruiter et al, 1991). Such an approach
describes the HLA-I expression as an all-or-none phenomenon and
underestimates the frequency of locus and allele-specific aberrations.
Furthermore, the analysis of established melanoma cell lines, which
have been cultured in vitro for many passages in the absence of
immunologic pressure, might not represent the expression pattern of
HLA moleclules on neoplastic cells in vivo. Recently, the availability
of monoclonal antibodies (MoAb) specific for single HLA-I alleles has
facilitated a more detailed analysis of the HLA status. These studies,
however, are limited to the HLA-A1, -A2, and -A3 allospecificities,
which show a combined frequency of over 55% in the caucasian
population. These allospecificities deserve special interest because
several melanoma-associated antigens (MAA) are recognized by CD81
lymphocytes in the context of HLA-A molecules. These antigens
include members of the MAGE family (Zakut et al, 1993), gp 100
(Bakker et al, 1994), and tyrosinase (Wolfel et al, 1994).
Little is known about the time point of the occurrence of HLA
alterations in disease evolution. Therefore, we systematically screened
short-time melanoma cell cultures for the loss of HLA-A and -B alleles.
A selective loss of HLA-I allospecificities was unraveled in 27% of
advanced lesions. In primary lesions a selective loss was detected only
in one of 11 cases.
HLA-II restricted presentation of antigens is important for the
costimulation of CTL against class-I specific tumor antigens. Some
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MAA are also directly recognized by CD41 T cells (Topalian et al,
1996). Intercellular adhesion molecule 1 (ICAM-1) (CD54) is an
adhesion molecule that plays a major role in the attraction of CD81
effector cells (Becker and Brocker, 1995). Expression of both surface
molecules is strongly enhanced upon stimulation with interferon (IFN)-
γ, whereas IFN-α only upregulates HLA-I. Therefore we tested the
stimulatory capacities of both IFN-α and IFN-γ on melanoma cell
cultures. Expression of HLA-II antigens was observed in 9% of all
samples, whereas significant expression of ICAM-1 was observed in
more than 56% of all cultures tested. These defects might be a critical
event for the escape of tumor cells from immunosurveillance.
MATERIALS AND METHODS
Patients Forty-eight surgically removed melanoma lesions were collected
under aseptic conditions from a total of 42 patients. Eleven patients suffered
from a primary tumor, 15 patients showed locoregional lymphnode metastase
and 16 patients had remote secondary tumors, including one sample (no. 39 in
Table I) from brain-metastases. Melanoma cells were released and dissociated
from washed and fragmented tissue sections by serial incubation with dispase
(Boehringer, Mannheim, Germany) diluted 1:2 in RPMI1640, and with
collagenase (Sigma, St. Louis, MO) diluted 1:100 in tris-buffered saline
containing 10 mM CaCl2. The outgrowing cells were subcultivated as described
elsewhere (Becker et al, 1993). Consecutive metastatic samples from three
patients were accessed at 5, 11, and 21 mo, respectively, after the first biopsy.
From one patient three melanoma biopsies from different locations and one
sample from a later time point were cultured in parallel.
Cell culture Established melanoma cultures were routinely cultivated as
monolayers at 37°C and 5% CO2 in RPMI 1640 (Gibco-BRL, Paisley, U.K.)
supplemented with 10% heat-inactivated fetal calf serum (Seromed, Berlin,
Germany), 5 mM glutamine (Seromed), 1 mM sodium pyruvate (Gibco-BRL),
and 1% of antibiotic mixture containing 10,000 U penicilline per ml and
10,000 µg streptomycine per ml (Gibco-BRL). The cell line UKRV-Mel2
(provided by Dr. D. Schadendorf, Department of Dermatology, Mannheim,
Germany) was used as a control and was grown under the same conditions
(Schadendorf et al, 1996). Confluent, adhering cells were detached with a
solution containing 0.05% trypsin and 0.02% ethylenediamine tetraacetic acid
(Seromed), inactivated with fresh media and subcultivated once a week.
Polymerase chain reaction (PCR) Total RNA was extracted from 5 3 106
to 107 cells using RNeasy kit (Qiagen, Hilden, Germany). Two to four
micrograms of RNA were used to synthesize cDNA (M-MuLV reverse
transcriptase: New England Biolabs, Beverly, MA). PCR was performed
with PCR DIG-labeling nucleotide mix (Boehringer) and with 2.0 µmol
oligonucleotide primers per ml. All cDNA were first amplified with primers
for β-actin to test for quality and quantity of cDNA. Only satisfactory cDNA
was then subject to amplification with primers for tyrosinase, gp100, MUC18,
MAGE-3, and MelanA. Primer sequences used for PCR were for tyrosinase
cDNA sense 59 ATG GAA CGC CCG AGG GAC CTT TAC 39 and anti-
sense 59 TGA GAG GCA TCC GCT ATC CCA GTA 39, for gp100 cDNA
sense 59 TAT TGA AAG TGC CGA GAT CC 39 and anti-sense 59 TGC
AAG GAC CAC AGC CAT C 39 (Adema et al, 1994), for MUC18 cDNA
sense 59 CCA AGG CAA CCT CAG CCA TGT 39 and anti-sense 59 CTC
GAC TCC ACA GTC TGG GAC GAC T 39 (Hoon et al, 1995), for MAGE-
3 cDNA sense 59 CCC AGG CTC GGT GAG GAG GCA 39 and anti-sense
59 CTG GTG ACT CGG CAG CAG GCA 39, and for MelanA cDNA sense
59 GTG CCC TGA CCC TAC AAG ATG 39 and anti-sense 59 CAT AAG
CAG GTG GAG CAT TGG 39. Primers for PCR were designed using OLIGO
primer analysis software 4.0 (National Biosciences, Plymouth, MN) and checked
on nucleotide sequences published on gene bank by the National Center for
Biotechnology Information (Bethesda, MD) to exclude cross-binding (Altschul
et al, 1990). For all amplifications, one cycle (93°C for 2.5 min, 64°C for
1.5 min, and 72°C for 1.5 min) was followed by 35 cycles (93°C for 30 s,
64°C for 30 s, and 72°C for 1.5 min), and 10 min at 72°C. An aliquot of the
PCR product was analyzed by electrophoresis on a 1.6% agarose gel. Bands
were visualized by staining with ethidium bromide. In all reactions various cell
lines were included as positive controls and H2O instead of cDNA as negative
control. For PCR-enzyme-linked immunosorbent assay, nucleotide probes
were selected and checked for specificity as described above, and obtained
biotinylated (Microsynth, Balgach, CH). PCR enzyme-linked immunosorbent
assay was performed according to kit directions (Boehringer). Hybridization
was specific at 45°C for all probes. The specific capture probe/PCR product
hybrids were bound to streptavidin-coated microtiter plates via the probes’
biotin label. After washing, the immobilized hybrids were treated with anti-DIG
peroxidase-conjugated antibody and ABTS, a peroxidase substrate. Absorbance
(A492) was measured and values more than twice the negative control were
rated positive for expression of the mRNA in question.
HLA phenotyping The original HLA-I and HLA-II phenotype of all patients
was established on blood samples collected in acidic citrate dextrose tubes using
a complement mediated microlymphocytotoxicity test (lymphotype AB120 and
DR60 from Biotest, Dreieich, Germany; Dupont 1987). Frozen peripheral
blood mononuclear cells (PBMC) were used if no fresh sample was available.
Lymphocytes were separated first with immunomagnetic beads (Dynal, Oslo,
Norway) into CD81 and CD41 fractions. Melanoma cells were pretreated
with 500 U of IFN-α per ml (Roferon, Hoffmann-LaRoche, Basel, Switzerland)
for 40 h at 37°C to upregulate surface expression of HLA-I molecules. Cells
were harvested as described above and washed once with Hank’s balanced
salt solution (without Ca11/Mg11/phenolred; Gibco-BRL) prior to HLA-I
typization. The same test system was used but incubation times were doubled
compared with blood samples. All microcytotoxicity assays were scored at the
department of transplantation surgery by the same experienced person to ensure
consistent reproducibility and reliability of the test.
Monoclonal antibodies The following primary MoAb were used: W6.32
(ATCC HB-95, mouse IgG2a) reacting with a monomorphic determinant of
HLA-I A, B, C molecules; L243 (Becton Dickinson, San Jose, CA; mouse
IgG2a; fluoroscein isothiocyanate-conjugated) recognizing human HLA class-
II DR epitopes; L368 (ATCC HB-149, mouse IgG1), recognizing cytoplasmic
β2M; 6B11 (provided by P. Romero, Ludwig Institute for Cancer Research,
Lausanne, Switzerland, mouse IgM, biotinylated) reactive with HLA-A1 allotype
(Carrel et al, 1994); BB7.2 (ATCC HB-82; mouse IgG2b) reactive with HLA-
A2 allotype; BB7.1 (ATCC HB-56; mouse IgG1) reactive with HLA-B7
allotype; 8.4 A6 (Ancell, Bayport, MN; mouse IgG1; fluoroscein isothiocyanate-
conjugated) recognizing D2 domain of the human ICAM-1 molecule; SL11.14
(Ancell; mouse IgG2a) recognizing natural killer H1a epitope of the human
NCAM (CD56) molecule; Me1–14 (provided by P. Romero, mouse IgG2a)
reacting with high molecular weight MAA (Carrel et al, 1991).
Flow cytometric analysis To upregulate expression of surface molecules
melanoma cells were pretreated with 500 U per ml of either IFN-α (Roferon)
or IFN-γ (Rentschler Biotechnology, Laupheim, Germany), for 40 h at 37°C.
Stimulated and nonstimulated cells were harvested as described above. Viability
and concentration was determined by trypan blue-exclusion assay, only samples
with a viability of over 90% were used for further analysis. Cells were washed
once with F-PBS (PBS without Ca11/Mg11 containing 1% fetal calf serum
and 0.02% sodium azide). For cytoplasmic antigens cells were permeabilized in
500 µl of permeabilizing solution (Becton Dickinson) for 10 min at room
temperature in the dark. Approximately 5–103105 cells each were incubated
with different antibodies at a concentration of 2–4 µg per 106 cells in a total
volume of 200 µl for 45 min on ice in the dark. After washing, non-
conjugated antibodies were stained with 1:30 dilution (in F-PBS) of fluoroscein
isothiocyanate-conjugated rabbit anti-mouse IgG secondary antibody (Dako,
Glostrup, Denmark) for 30 min on ice in the dark. Biotinylated antibodies
were stained with fluoroscein isothiocyanate-conjugated streptavidin (Dako),
diluted 1:50. In all cases, cells were also stained with the appropriate isotype-
matched control antibodies, nonspecific mouse IgG1, IgG2a, or IgM (Ancell).
After washing and fixation with 0.5% formaldehyde in F-PBS, fluorescence of
the cells was measured on a FACSCalibur (Becton Dickinson). Nonviable cells
were gated out. Flow cytometric data are presented as mean of fluorescence
intensity versus cell counts.
Immunohistochemistry Immunohistochemical staining was performed
using the APAAP method (Cordell et al, 1984). Cryostat sections (µ5 µm)
were fixed in cetone for 10 min at room temperature, dried for 2–6 h, and
stored at –20°C until further use. Filtered hybridoma supernatants were applied
undiluted to the dry sections in a moist chamber and incubated for 1 h at room
temperature. Anti-mouse Ig and the APAAP complex (Dako) were added and
incubated for 30 min each. The alkaline substrate was applied for 20 min,
followed by hematoxylin counterstaining. Between the different steps tissue
sections were washed in tris-buffered saline.
RESULTS
Reverse transcriptase-PCR enzyme-linked immunosorbent
assay and flow cytometric analysis for melanocytic antigens All
cell cultures tested showed mRNA expression of at least one and up
to all five of the markers from the test panel, thereby confirming their
melanocytic origin. The control cell line UKRV-Mel2 reacted strongly
positive with all five markers. Keratinocyte and fibroblast cell lines
used as negative controls did not reveal any mRNA expression of the
melanocytic markers (data not shown). Of 41 melanoma cell cultures
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Table I. HLA typization of blood and cell culture from three groups of melanoma patients and flow cytometric analysis of cell
surface markers
No. Patient Stage, TNMa HLA-I (PBMC)b Lossc HLA-Id HLA-IId CD54d
00 UKRV nd (cell line) negative nd neg. 10.9 3.8
01 950504 I, T3N0M0 A2/3 B7/51 no 2.09 2.6 17.2
02 950803 I, T2N0M0 A28/31 B8/60 no 0.98 2.2 nd
03 951010 I, T3N0M0 A29/32 B7/45 no 2.40 2.8 nd
04 951019 I, T3N0M0 A1/28 B44/57 no 3.23 2.2 nd
05 960514 I, T4N0M0 A25/31 B18/27 no 1.95 10.5 11.4
06 960704 I, T1N0M0 A1x B63/47 B47 1.49 5.7 18.2
07 960724 I, T1N0M0 A2x B7/51 no 2.01 3.8 12.9
08 961008 I, T1N0M0 A26/30 B35/51 no 1.32 4.3 20.7
09 961121 I, T4N0M0 A2/3 B35/38 no 3.81 3.1 11.0
10 961122 I, T1N0M0 A2/11 B8/63 no 2.36 7.5 13.7
11 961205 I, T3N0M0 A2x B51/57 no 2.32 12.7 12.7
12a 941209 II, TxN2aM0 A1/2 B13/60 no 1.69 1.4 17.9
12b 950822 II, TxN2aM0 A1/2 B13/60 A2 1.88 1.3 2.3
13 950320 II, TxN2bM0 A26/32 B27/44 B44 2.94 3.9 7.9
14 950330 II, TxN2bM0 A1x B13/57 no 2.97 1.4 42.7
15 950622 II, TxN2aM0 A2/3 B7/18 B18 1.22 4.6 10.9
16 950710 II, TxN1M0 A2/11 B35/44 no 1.39 0.7 nd
17a 950728 II, TxN2aM0 A11/24 B18/63 no 2.23 8.8 26.1
17b 960611 II, TxN2aM0 A11/24 B18/63 no 1.69 1.0 5.7
18 960104 II, TxN2bM0 A2/3 B8/44 B44 3.18 8.3 22.6
19 960207 II, TxN2aM0 A1/2 B57/60 no 1.66 5.0 nd
20 960312 II, TxN1M0 A1/3 B8/62 no 1.53 3.2 8.1
21 960502 II, TxN2aM0 A26/30 B13/27 no 2.17 2.7 nd
22 960507 II, TxN1M0 A2x B7/60 B7 1.29 3.2 17.8
23 960816 II, TxN2aM0 A29/31 B15/57 no 1.20 3.3 11.0
24 961024 II, TxN2aM0 A1/31 B7/62 no 2.01 4.8 10.3
25 961119 II, TxN2aM0 A11/29 B44/51 no 1.79 1.9 34.3
26 961127 II,TxN2bM0 A2/25 B44/58 B44 1.77 3.3 17.5
27a 950322 III, TxNxM1b A2/3 B7/51 no 1.30 1.6 6.4
27b 961209 III, TxNxM1b A2/3 B7/51 no 2.51 5.8 28.2
28 951004 III, TxNxM1a A2/3 B13/35 no 1.81 1.5 5.7
29 960306 III, TxNxM1a A1/3 B8/62 B8 2.48 1.9 2.3
30 960509 III, TxNxM1a A3/24 B38/51 no 1.75 3.3 nd
31a 960523a III, TxNxM1a A1/29 B7/39 us 1.59 5.1 17.6
31b 960523b III, TxNxM1a A1/29 B7/39 no 2.17 nd nd
31c 960523c III, TxNxM1a A1/29 B7/39 no 1.92 nd nd
31d 970320 III, TxNxM1a A1/29 B7/39 no 1.97 9.6 17.1
32 960618 III, TxNxM1a A2/28 B8/44 B44 1.18 2.8 10.7
33 960626 III, TxNxM1a A11/30 B49/51 no 1.88 3.9 39.4
34 960819 III, TxNxM1a A1/2 B7/18 no 2.23 3.0 3.3
35 960920 III, TxNxM1a A1/2 B8/62 no 1.47 4.1 17.1
36 960924 III, TxNxM1a A2/3 B7/49 B49 1.08 1.5 17.2
37 961023 III, TxNxM1a A24/30 B51/62 no 1.88 3.2 28.2
38 961213 III, TxNxM1a A3/11 B37/44 no 2.02 3.4 10.3
39 970109 III, TxNxM1a A2/68 B62x no 0.88 0.9 4.9
40 970314 III, TxNxM1a A3x B7/61 no 2.02 16.8 12.4
41 970604 III, TxNxM1a A2/25 B44x A2, us 2.31 35.3 25.9
42 970715 III, TxNxM1a A1/32 B52/57 us 1.05 16.5 15.4
aTNM classification according to UICC (International Union against Cancer).
bx, homozygous.
cOn melanoma cells; us, unspecific reaction.
dSamples positive for surface molecules in the absence of interferons are indicated with bold values; data shown as factor of stimulation (mean fluorescence of IFN-stimulated versus
unstimulated cells); nd, not determined.
tested, 31 were found to be positive for MUC18, 22 for tyrosinase,
20 for MAGE-3, 16 for gp100, and 15 for MelanA. Alternatively,
some cell cultures were also stained for high molecular weight-MAA
with the Me1–14 MoAb. All melanoma cultures tested were found to
be positive for high molecular weight-MAA by flow cytometric analysis.
HLA phenotype of melanoma cells The HLA-I phenotype of all
patients is shown in Table I. Typization of HLA-II was possible only
with fresh samples, frozen PBMC resulted in unspecific basal toxicity,
probably due to partial destruction of B lymphocytes during freezing
(data not shown). Without incubation with IFN-α the results of the
microcytotoxicity assay were not reliable due to the low expression
level. The specific HLA-I allospecificities were determined in 45 of
48 melanoma cell cultures after incubation with IFN-α. They were
found to be identical to those seen in the corresponding PBMC. Two
samples (31a, 42) showed an unspecific basal activity and sample 41
from a heavily pigmented melanoma cell culture was completely
nonreactive; however, flow cytometry with MoAb BB7.2 MoAb
specific for HLA-A2 revealed a clear loss of this allospecificity. Some
cultures were analyzed several times over a period of 4 mo. The results
did not change during the cultivation. Probe 12a showed no loss of
any HLA-I allospecificities, but in probe 12b from the same patient
8 mo later a clear loss of HLA-A2 was observed (Fig 3d). This loss
was confirmed by immunohistochemistry and by cytofluorometry.
Probes 17a/17b and 27a/27b, originating from the same patient with
an interval of 11 and 12 mo, respectively, resulted in the same HLA-
I phenotype. The four probes 31a–d originating from metastases of
different locations and a consecutive sample, respectively, of the same
patient also showed the same HLA-I phenotype. In general, the HLA-
A alleles were easier to determine and were expressed constantly and
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Figure 1. Immunohistochemical staining of cryostat sections from tumor biopsies of melanoma patients. (a) Sample 22, with a specific loss of
HLA-B7 allospecificity, stained with BB7.1 MoAb; (b) sample 12a stained with BB7.2 MoAb specific for HLA-A2; (c) sample 12b also stained with BB7.2
MoAb and with W6.32 MoAb (d). Scale bars: (a) 400 µm, (b) 50 µm, (c, d) 25 µm.
homogeneously. The well-characterized cell line UKRV-Mel2 used as
a control clearly showed a loss of all HLA-A and -B alleles. HLA-B
alleles often showed some minor unspecific side reactions. From a
total of 48 samples, 11 patients showed a specific loss of one HLA-A
or -B allele in their melanoma cells, 10 of them having locoregional
lymphnode metastases (stage II; A2, B7, B18, 33B44) or distant
metastases (stage III; A2, B8, B44, B49). Only one patient with a
primary superficial spreading melanoma (Clark level I) presented a
HLA-B47 loss. All losses were confirmed by repeated testing. Neither
a total loss of complete HLA-I (due to a nonfunctional β2M, as seen
in the UKRV-Mel2 control cell line) nor a loss of one haplotype was
observed in all samples tested.
Immunohistochemical staining of tumor samples Cryostat
sections of tumor biopsies from patients 15 and 22, both typed positive
for HLA-B7 from the blood, were stained with the B7-specific MoAb
BB7.1. As demonstrated in Fig 1(a), the whole tumor of patient 22
lacked expression of HLA-B7 surface molecule. The surrounding
healthy tissue and intratumoral vessels showed clear immunoreactivity
for HLA-B7. When stained with W6.32 MoAb reacting with a
monomorphic determinant of HLA-I, tumor tissue was stained, demon-
strating expression of other HLA-I allospecificities. Patient 15 presented
a heterogenous but clear positive pattern for HLA-B7, this corresponds
well with the result from the microcytotoxicity assay, where only two
of five wells specific for HLA-B7 showed a positive reaction (data not
shown). Figure 1(b) shows sample 12a, which stained positive with
BB7.2 MoAb specific for HLA-A2. In contrast sample 12b did not
express any HLA-A2 (Fig 1c), although the other HLA-I allospecifities
were present (Fig 1d). Several sections stained with 6B11 (anti-HLA-
A1) and BB7.2 (anti-HLA-A2) MoAb showed good correlation with
the results from the microcytotoxicity assay (data not shown).
Influence of IFN-a and IFN-g on surface expression of HLA-I,
HLA-II, and ICAM-1 antigens The effects of both interferons are
presented in Table I. Data are indicated as a factor of stimulation, i.e.,
mean fluorescence of IFN-treated cells versus untreated controls. When
compared with appropriate isotype control all melanoma cells were
observed to express low to intermediate levels of HLA-I. The control
cell line UKRV-Mel2 was totally negative for HLA-I, even in the
presence of IFN-α (Fig 2a). This is due to a nonfunctional β2M, as
demonstrated with L368 MoAb (Fig 2c); however, expression of HLA-
II at a high (Fig 2b) and of ICAM-1 at an intermediate level (data not
shown) was observed. In all cell cultures IFN-α upregulated expression
of HLA-I up to 4-fold. IFN-γ stimulated expression of HLA-I less
efficiently (data not shown). Expression of HLA-II was not detectable
in 42 of 46 untreated samples but was upregulated (up to 35-fold the
Figure 2. Detection of immunocritical surface molecules on melanoma
cells. Cytofluorometric analysis of control cell line UKRV-Mel2 stained for
surface expression of HLA-I (a), HLA-II (b), for cytoplasmic β2M (c), and of
sample 39 stained with MoAb specific for ICAM-1 (d) and HLA-II (e). Cells
cultivated in the presence of IFN-α (a, c) or IFN-γ (b, d, e) are shown as bold
lines. Isotype control is represented by shaded areas.
value obtained with isotype, mean 5.1 6 5.8) after stimulation with
IFN-γ. In sample 39 originating from a metastasis in the central nervous
system, HLA-II did not respond to treatment with IFN-γ (Fig 2d),
although ICAM-1 showed the normal stimulation pattern (Fig 2e).
This culture also expressed CD56, the neuroneal adhesion molecule
(data not shown). Expression of ICAM-1 was enhanced by IFN-γ up
to 40-fold (mean 15.8 6 9.6); without stimulation 17 of 39 tested
melanoma cell cultures did not express significant levels of ICAM-1.
Over 95% of the tumor cells of sample 12a were clearly positive for
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Figure 3. Cytofluorometric analysis of melanoma cells from patient
12 cultured in the absence (fine line) or the presence (bold line) of
IFN-a. Samples were stained with MoAb specific for HLA-I (a, b) or HLA-
A2 (c, d). Isotype control is represented by shaded areas.
HLA-A2 using the monospecific BB7.2 MoAb (Fig 3c), whereas of
sample 12b all cells stained negative, even in the presence of IFNα
(Fig 3d). This confirmed the specific loss of the HLA-A2 allospecificity
detected by the microcytotoxicity assay. Expression of the other HLA-
I allospecificities was unaltered in both samples, as demonstrated by
staining with MoAb W6.32 (Figs 3a, b).
DISCUSSION
The HLA status of a tumor is critical for its recognition and rejection
by the immune system. In melanoma, the level of expression of pan-
HLA-I and pan-HLA-II also has prognostic implications (van Duinen
et al, 1988). A detailed knowledge of the HLA status including
allospecifities is a precondition for a successful immunotherapeutical
intervention. This is especially true, if peptides, peptide-pulsed dendritic
cells (Nestle et al, 1998), or genetically engineered tumor cells are used
as vaccines.
Analysis of class I allospecificities in melanoma lesions has been
hampered by the limited availability of specific MoAb. Most studies
have focused on the expression of HLA-A2, because its high frequency
facilitates the accrual of large numbers of patients and anti-HLA-A2
MoAb have been available for many years. Several MAA have been
recognized by CTL in the context of HLA-A2 antigens (Bakker et al,
1994; Kawakami et al, 1994; van der Bruggen et al, 1994; Wolfel et al,
1994). Selective loss of HLA-A2 antigens has been found in µ30% of
melanoma lesions (Kageshita et al, 1993a; Jager et al, 1997) and in
40%–80% of other solid tumors (Natali et al, 1989); however, these
data have to be interpreted with caution as they were mainly collected
by immunohistochemistry, a method that is not optimal for quantitative
determinations of the HLA status.
Restifo et al studied melanoma cell cultures obtained from patients
undergoing immunotherapy for metastatic melanoma (Restifo et al,
1996). Four of 13 (31%) melanoma cell lines lacked functional HLA-
I expression as measured by flow cytometry and immunohistochemistry.
Northern blot analysis of RNA extracted from these cells revealed
normal levels of alpha-chain mRNA but no β2M mRNA or protein.
Previous tumor sections obtained from patients prior to immunotherapy
were found to be positive for β2M, suggesting that the loss of β2M
may be a mechanism whereby tumor cells can acquire immunoresistance
during immunotherapy. This effect is compatible with the concept of
immunoselection in vivo (Lehmann et al, 1995).
Marincola et al evaluated HLA class I expression in 24 metastatic
melanoma cell lines (Marincola et al, 1994). Total loss of HLA class I
expression was not noted; instead, a variable degree of expression of
HLA-B was found that could be upregulated by IFN-γ. HLA-A
allospecificities were consistently expressed in all cell types. Loss of
allelic expression was noted in two of 14 HLA-A2 (14%) and in one
of three HLA-A29 (33%) positive melanoma cell lines and included a
full haplotype, which suggests loss of a genomic fragment. A loss of
HLA-B allospecificities was not observed.
We have systematically investigated 48 melanoma cell cultures
derived from nonselected primary or metastatic lesions, that were
analyzed for their complete HLA-A and -B status. We adapted a
microcytotoxicity assay that is routinely applied for HLA typing.
Because of the low HLA-I expression level, the cultured melanoma
cells had to be stimulated with IFN-α to prevent false negative
results, probably due to an overexpression of the c-myc oncogene,
which specifically downmodulates HLA-I B expression. This effect is
frequently observed in human melanoma (Griffioen et al, 1995) and
can be antagonized by IFN-α.
We found a selective loss of two HLA-A and of eight HLA-B alleles
in a total of 37 melanoma metastases, but only one HLA-B loss out
of 11 primary tumors. In three cases we confirmed our results
by immunohistochemistry and cytofluorometry using monospecific
antibodies. We did not detect a complete loss of HLA-I, although the
frequency of a total HLA-I loss is estimated to be about 16% in primary
lesions (Ferrone and Marincola, 1995). The increased frequency of
HLA-B losses in metastases compared with primary tumors suggest
that this event has biologic significance during disease progression. In
fact, cytotoxic T cell clones are reported that recognize melanoma
antigen in the context of HLA-B molecules, although much more
HLA-A restricted clones are characterized. This might be due to the
frequency of certain HLA alleles, to the limited availability of MoAb
against the HLA-B molecules, or to the frequent loss of HLA-B surface
expression.
The loss of HLA-B occurred in four of nine HLA-B44 positive
patients, but only in one of 11 HLA-B7 and one of seven HLA-B8
patients. These observations propose that HLA-B44 might be an
important pathway for the presentation of MAA. It has been shown
that specific epitopes of tyrosinase and MAGE-1, 22, and 23 are also
presented by the HLA-B44 molecule to cytotoxic T lymphocytes
(Brichard et al, 1996; Herman et al, 1996; Luescher et al, 1996). On
the other hand, our data are encouraging for vaccination approaches
using HLA-A adapted peptides (Jager et al, 1996) or dendritic cells
pulsed with HLA-I restricted peptides (Nestle et al, 1998), that HLA
expression remains intact in most of the patients although the density
of surface HLA-I molecules on the tumor cells is rather low. This
hazard can be opposed by the application of IFN-α that was significantly
more efficient in general upregulation of HLA-I than IFN-γ. In all
cultures, IFN-γ was able to induce HLA-II and ICAM-1, a surface
molecule mediating specific interaction of melanoma cells with CTL
(Becker et al, 1993; Kageshita et al, 1993b; Yue et al, 1997). HLA-II
restricted presentation of antigens may play an important role in the
costimulation of CTL against class-I specific tumor antigens (Rock
and Clark, 1996), because CD41 T cells exist that recognize MAA
such as tyrosinase (Topalian et al, 1996).
In the adjuvant clinical situation, IFN-α – at least in high doses –
has improved the survival of high-risk melanoma patients in contrast
to IFN-γ (Kirkwood et al, 1996). It may be speculated that this is due
to enhanced HLA-I expression by IFN-α. Increased HLA-I expression
was found to be correlated with a low relapse rate in melanoma patients
(van Duinen et al, 1988). Irrespective of the role of class I antigens in
the clinical course of the disease, defects in their expression by
melanoma cells are likely to have a negative impact on the increasingly
applied T cell-based immunotherapy of melanoma (Maeurer et al,
1996). In vitro data convincingly argue that class I expression in
melanoma lesions might represent an important criterion to select
patients for T cell-based therapy.
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